Clinicopathologic analysis of Fas, Fas ligand, and other biomarkers in locally advanced breast carcinoma

Nat L. Pernick, Laura Biernat, Wei Du, Daniel W Visscher

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Fas and Fas ligand (FasL) mediate T-lymphocyte cytotoxicity and may also induce physiologic apoptosis in breast epithelium associated with menstruation and cessation of lactation. Altered expression may thus be associated with breast carcinoma progression, chemotherapy response, or outcome. We performed a clinicopathologic analysis of immunohistochemical staining for Fas and FasL, as well as bax, bcl-2, glutathione-s-transferase, HER-2 (c-erbB-2), Ki67, P-glycoprotein, p53, and hormone receptors in pretreatment breast biopsies from 34 patients with locally advanced or limited stage IV breast carcinoma who received preoperative (neoadjuvant, primary) chemotherapy followed by lumpectomy or mastectomy. Neoplastic cells expressed Fas in 44% and FasL in 85% of pretreatment biopsies. Fas immunostaining was more frequent in tumors with larger size (p = 0.02) and pretreatment metastases (p = 0.03). Combined Fas and p53 staining correlated with pathologic complete response (4 of 5 CR versus 6 of 29 other, p = 0.02), as did combined p53 and lack of FasL staining (2 of 5 CR versus 0 of 29 other, p = 0.02), but individually Fas, p53, and lack of FasL immunostaining demonstrated only trends to correlation with CR (p = 0.13-0.15). No other biomarkers correlated with chemotherapeutic response. Neither FasL nor Fas expression was associated with the degree of peritumoral lymphocytic infiltration, or with expression of the other biomarkers. Recurrence was more frequent in Fas-expressing tumors (recurrent cases 7 of 10 Fas positive versus nonrecurrent 8 of 24 Fas positive, p = 0.07). In this patient group, Fas expression is associated with aggressive tumor behavior. Biomarker immunostaining correlates weakly with pathologic response to preoperative chemotherapy, in keeping with complex or heterogeneous tumor-drug interactions.

Original languageEnglish (US)
Pages (from-to)233-241
Number of pages9
JournalBreast Journal
Volume6
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Fas Ligand Protein
Biomarkers
Breast Neoplasms
Staining and Labeling
Drug Therapy
Neoplasms
Breast
Biopsy
Menstruation
Segmental Mastectomy
Mastectomy
Glutathione Transferase
Drug Interactions
Lactation
Epithelium
Hormones
Apoptosis
Neoplasm Metastasis
T-Lymphocytes
Recurrence

Keywords

  • Breast carcinoma
  • Fas (CD95/APO-1/FasR)
  • Fas ligand (CD95L)
  • p53
  • Preoperative chemotherapy (neoadjuvant, primary)

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology

Cite this

Clinicopathologic analysis of Fas, Fas ligand, and other biomarkers in locally advanced breast carcinoma. / Pernick, Nat L.; Biernat, Laura; Du, Wei; Visscher, Daniel W.

In: Breast Journal, Vol. 6, No. 4, 2000, p. 233-241.

Research output: Contribution to journalArticle

@article{e4e0331ab6b346ffa1e566cd42eb2dc5,
title = "Clinicopathologic analysis of Fas, Fas ligand, and other biomarkers in locally advanced breast carcinoma",
abstract = "Fas and Fas ligand (FasL) mediate T-lymphocyte cytotoxicity and may also induce physiologic apoptosis in breast epithelium associated with menstruation and cessation of lactation. Altered expression may thus be associated with breast carcinoma progression, chemotherapy response, or outcome. We performed a clinicopathologic analysis of immunohistochemical staining for Fas and FasL, as well as bax, bcl-2, glutathione-s-transferase, HER-2 (c-erbB-2), Ki67, P-glycoprotein, p53, and hormone receptors in pretreatment breast biopsies from 34 patients with locally advanced or limited stage IV breast carcinoma who received preoperative (neoadjuvant, primary) chemotherapy followed by lumpectomy or mastectomy. Neoplastic cells expressed Fas in 44{\%} and FasL in 85{\%} of pretreatment biopsies. Fas immunostaining was more frequent in tumors with larger size (p = 0.02) and pretreatment metastases (p = 0.03). Combined Fas and p53 staining correlated with pathologic complete response (4 of 5 CR versus 6 of 29 other, p = 0.02), as did combined p53 and lack of FasL staining (2 of 5 CR versus 0 of 29 other, p = 0.02), but individually Fas, p53, and lack of FasL immunostaining demonstrated only trends to correlation with CR (p = 0.13-0.15). No other biomarkers correlated with chemotherapeutic response. Neither FasL nor Fas expression was associated with the degree of peritumoral lymphocytic infiltration, or with expression of the other biomarkers. Recurrence was more frequent in Fas-expressing tumors (recurrent cases 7 of 10 Fas positive versus nonrecurrent 8 of 24 Fas positive, p = 0.07). In this patient group, Fas expression is associated with aggressive tumor behavior. Biomarker immunostaining correlates weakly with pathologic response to preoperative chemotherapy, in keeping with complex or heterogeneous tumor-drug interactions.",
keywords = "Breast carcinoma, Fas (CD95/APO-1/FasR), Fas ligand (CD95L), p53, Preoperative chemotherapy (neoadjuvant, primary)",
author = "Pernick, {Nat L.} and Laura Biernat and Wei Du and Visscher, {Daniel W}",
year = "2000",
doi = "10.1046/j.1524-4741.2000.98087.x",
language = "English (US)",
volume = "6",
pages = "233--241",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Clinicopathologic analysis of Fas, Fas ligand, and other biomarkers in locally advanced breast carcinoma

AU - Pernick, Nat L.

AU - Biernat, Laura

AU - Du, Wei

AU - Visscher, Daniel W

PY - 2000

Y1 - 2000

N2 - Fas and Fas ligand (FasL) mediate T-lymphocyte cytotoxicity and may also induce physiologic apoptosis in breast epithelium associated with menstruation and cessation of lactation. Altered expression may thus be associated with breast carcinoma progression, chemotherapy response, or outcome. We performed a clinicopathologic analysis of immunohistochemical staining for Fas and FasL, as well as bax, bcl-2, glutathione-s-transferase, HER-2 (c-erbB-2), Ki67, P-glycoprotein, p53, and hormone receptors in pretreatment breast biopsies from 34 patients with locally advanced or limited stage IV breast carcinoma who received preoperative (neoadjuvant, primary) chemotherapy followed by lumpectomy or mastectomy. Neoplastic cells expressed Fas in 44% and FasL in 85% of pretreatment biopsies. Fas immunostaining was more frequent in tumors with larger size (p = 0.02) and pretreatment metastases (p = 0.03). Combined Fas and p53 staining correlated with pathologic complete response (4 of 5 CR versus 6 of 29 other, p = 0.02), as did combined p53 and lack of FasL staining (2 of 5 CR versus 0 of 29 other, p = 0.02), but individually Fas, p53, and lack of FasL immunostaining demonstrated only trends to correlation with CR (p = 0.13-0.15). No other biomarkers correlated with chemotherapeutic response. Neither FasL nor Fas expression was associated with the degree of peritumoral lymphocytic infiltration, or with expression of the other biomarkers. Recurrence was more frequent in Fas-expressing tumors (recurrent cases 7 of 10 Fas positive versus nonrecurrent 8 of 24 Fas positive, p = 0.07). In this patient group, Fas expression is associated with aggressive tumor behavior. Biomarker immunostaining correlates weakly with pathologic response to preoperative chemotherapy, in keeping with complex or heterogeneous tumor-drug interactions.

AB - Fas and Fas ligand (FasL) mediate T-lymphocyte cytotoxicity and may also induce physiologic apoptosis in breast epithelium associated with menstruation and cessation of lactation. Altered expression may thus be associated with breast carcinoma progression, chemotherapy response, or outcome. We performed a clinicopathologic analysis of immunohistochemical staining for Fas and FasL, as well as bax, bcl-2, glutathione-s-transferase, HER-2 (c-erbB-2), Ki67, P-glycoprotein, p53, and hormone receptors in pretreatment breast biopsies from 34 patients with locally advanced or limited stage IV breast carcinoma who received preoperative (neoadjuvant, primary) chemotherapy followed by lumpectomy or mastectomy. Neoplastic cells expressed Fas in 44% and FasL in 85% of pretreatment biopsies. Fas immunostaining was more frequent in tumors with larger size (p = 0.02) and pretreatment metastases (p = 0.03). Combined Fas and p53 staining correlated with pathologic complete response (4 of 5 CR versus 6 of 29 other, p = 0.02), as did combined p53 and lack of FasL staining (2 of 5 CR versus 0 of 29 other, p = 0.02), but individually Fas, p53, and lack of FasL immunostaining demonstrated only trends to correlation with CR (p = 0.13-0.15). No other biomarkers correlated with chemotherapeutic response. Neither FasL nor Fas expression was associated with the degree of peritumoral lymphocytic infiltration, or with expression of the other biomarkers. Recurrence was more frequent in Fas-expressing tumors (recurrent cases 7 of 10 Fas positive versus nonrecurrent 8 of 24 Fas positive, p = 0.07). In this patient group, Fas expression is associated with aggressive tumor behavior. Biomarker immunostaining correlates weakly with pathologic response to preoperative chemotherapy, in keeping with complex or heterogeneous tumor-drug interactions.

KW - Breast carcinoma

KW - Fas (CD95/APO-1/FasR)

KW - Fas ligand (CD95L)

KW - p53

KW - Preoperative chemotherapy (neoadjuvant, primary)

UR - http://www.scopus.com/inward/record.url?scp=0033866913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033866913&partnerID=8YFLogxK

U2 - 10.1046/j.1524-4741.2000.98087.x

DO - 10.1046/j.1524-4741.2000.98087.x

M3 - Article

VL - 6

SP - 233

EP - 241

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - 4

ER -